DelveInsight launched a new report on Overt Hepatic Encephalopathy Epidemiology Forecast, 2030.
DelveInsight’s ‘Overt Hepatic Encephalopathy Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Overt Hepatic Encephalopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Hepatic encephalopathy (HE) is a brain disorder that develops in some individuals with liver disease. HE presents as a spectrum of neuropsychiatric symptoms ranging from subtle fluctuating cognitive impairment to coma and is a significant contributor to morbidity in patients with liver disease. It is observed in acute liver failure, liver bypass procedures – for example, shunt surgery and trans-jugular intrahepatic portosystemic shunt – and cirrhosis, classified as Type A, B, and C HE, respectively. Pathogenesis is linked with ammonia and glutamine production. Treatment is based on mechanisms to reduce these compounds’ formation and/or removal; many of the symptoms are reversible when promptly detected and treated.
Some of the key highlights from the Overt Hepatic Encephalopathy Epidemiology Report:
Total diagnosed prevalent cases of Cirrhosis (hospitalized) in the 7MM was found to be 860,784 in 2020. These cases are expected to increase by 2030 at a CAGR of 0.63% during the study period (2018–2030).
The diagnosed prevalent cases of Hepatic Encephalopathy in the 7MM are expected to increase at a CAGR of 0.61% for the study period of 2018-2030.
Among 7MM, the United States has the highest diagnosed prevalent cases of hepatic encephalopathy with 205,018 cases in 2020.
Scope of the Overt Hepatic Encephalopathy Epidemiology report:
The Overt Hepatic Encephalopathy report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
The Overt Hepatic Encephalopathy Epidemiology Report and Model provide an overview of the risk factors and global trends of Overt Hepatic Encephalopathy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight into the historical and forecasted patient pool of Overt Hepatic Encephalopathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps to recognize the growth opportunities in the 7MM concerning the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Overt Hepatic Encephalopathy
The report provides the segmentation of the Overt Hepatic Encephalopathy epidemiology
Table of Contents:
1. Key Insights
2. Executive Summary of Overt Hepatic Encephalopathy
3. Overt Hepatic Encephalopathy Epidemiology Overview at a Glance
4. Overt Hepatic Encephalopathy: Disease Background and Overview
5. Epidemiology and Patient Population
6. Case Reports
7. Country Wise-Epidemiology of Overt Hepatic Encephalopathy
9. DelveInsight Capabilities
11. About DelveInsight
DelveInsight’s ‘Overt Hepatic Encephalopathy-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom)
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States